Ultrapar's "patient capital": Ipiranga's owner's plans looking ahead to 2031
Nos últimos cinco anos, a Ultrapar analisou mais de 100 transações e fechou 14. O CEO Rodrigo Pizzinatto chama essa diferença de “capital paciente” – uma forma de tomar decisões orientadas pela criação de valor, e não “por crescimento pelo crescimento”. “Não precisamos fazer uma transação pela transação,” Pizzinatto disse ao Brazil Journal. “Se a […] The post O “capital paciente” da Ultrapar: os…
Ultrapar, the parent company of Ipiranga, has analyzed over 100 transactions in the past five years, closing 14 deals. CEO Rodrigo Pizzinatto describes the company's approach as "patient capital," prioritizing value creation over growth for its own sake. Ultrapar aims to allocate capital in a new phase, focusing on organic growth, acquisitions, and shareholder returns, with a guidance of 1x to 1.5x net debt/EBITDA for the next five years.
The company generated R$ 33.9 billion in cash flow and divestitures since 2021 and plans to invest in areas such as infrastructure, logistics, and energy.
Written by urgent.news from Brazil Journal's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.